Home / Rehab Success Rates

Rehab Success Rates

Addiction treatment success rates in U.S. adults with substance use disorders.

Rates of success in addiction treatment vary based on a wide number of factors including definitions of “success”, treatment setting and length, types of therapy utilized, and individual factors like drug of choice and personal motivation for recovery. In general, rehab is effective at reducing or eliminating substance abuse and improving quality of life.

Amanda Stevens, B.S.

Medical Content Writer

Amanda Stevens is a highly respected figure in the field of medical content writing, with a specific focus on eating disorders and addiction treatment. Amanda earned a Bachelor of Science degree in Social Work from Purdue University, graduating Magna Cum Laude, which serves as a strong educational foundation for her contributions.

Learn More About Amanda

Key Points

Addiction treatment success is more complex than just achieving abstinence. This report explores how success is defined, measured, and affected by different treatment settings and methodologies. Here’s a breakdown of the essential takeaways:

Traditional definitions focused on total abstinence. Today, success is also measured by reduced use, improved mental and physical health, stable housing or employment, and better quality of life. Even partial improvement is meaningful.

Long-term outcomes are hard to track due to: high dropout rates in follow-up studies, reliance on self-reported data, differing methodologies, and differing definitions of success.

In one study, individuals who completed treatment were 43% more likely to maintain sobriety at a 12-month follow-up compared to those who left early (60% vs. 42%).

The longer someone stays engaged in a treatment program, the better their chance of sustained recovery. Time doesn’t need to be in one setting; transitioning between levels of care (step-down models) is often the most effective path.

In a Hazeldon study, 86–87% of patients reported “good or better” life quality one year after treatment—even if not fully abstinent.

Defining “Success” in Addiction Treatment

Multiple Dimensions of Success:

In the addiction field, “success” is defined in various ways depending on the study or institution. Traditionally, success often meant complete abstinence from the substance of abuse. For example, many treatment programs long measured success as the percentage of patients maintaining sobriety (no use of drugs/alcohol) for a given follow-up period. However, there is growing recognition that other outcomes matter as well¹. Besides abstinence, researchers and providers consider reductions in substance use, improvements in physical and mental health, and enhanced quality of life as key signs of success². In fact, a recent NIH-supported analysis of stimulant use disorder trials found that even a reduction in use (not just total abstinence) led to significant improvements in health measures like reduced cravings, lower depression scores, and better overall functioning³. Nora Volkow, director of NIDA, has noted that “abstinence should be neither the sole aim nor the only valid outcome of treatment,” emphasizing more nuanced, individualized measures of recovery⁴.

Clinical and Functional Outcomes:

Many organizations now define success broadly to include psychosocial outcomes. This can mean measuring whether a person has gained employment or stable housing, improved their mental health, or restored relationships – even if they have an occasional slip in substance use. The Hazelden Betty Ford Foundation, for instance, tracks patient-reported quality of life as a success metric. In their outcomes data, 86%–87% of patients report “good or better” overall quality of life at one year post-treatment, a figure notably higher than national norms⁵. Such improvements in life functioning are seen as evidence that treatment helped patients resume “productive lives” even if complete abstinence isn’t always achieved⁶. Similarly, the Substance Abuse and Mental Health Services Administration (SAMHSA) and other agencies increasingly view recovery as a process characterized by health, stable home environment, purpose, and community support – not just days of abstinence⁷. In practice, this means success may include outcomes like reduced substance use frequency/intensity, fewer legal or medical crises, or engagement in continuing care or peer support groups.

Program Completion vs Long-Term Recovery:

It’s also important to distinguish treatment process measures from long-term outcomes. Treatment providers often cite “program completion” rates as an immediate success indicator – i.e. the percentage of clients who stay in treatment until formally discharged by staff (having met treatment goals). Higher completion rates are generally correlated with better long-term outcomes (more on this below). However, completing a program is not the same as maintaining sobriety months or years later. Thus, some studies use short-term success metrics (like negative drug tests at end of treatment, or completion rates) while others track long-term success (such as one-year abstinence rates, or sustained reductions in use). Both are valuable: program retention/completion is a prerequisite for long-term change, and longer-term follow-ups reveal how well initial gains hold up. In summary, “success” in addiction treatment is multidimensional – encompassing abstinence or reduced use, improved mental/physical health, and better social functioning. Modern definitions of recovery acknowledge that relapse can occur without negating progress, and that incremental improvements (harm reduction) are meaningful stepping stones in the recovery journey⁸.

Ready to Start Healing?

Our admissions team is available 24/7 to assist you in finding the appropriate treatment program for yourself or a loved one. There is no pressure, and you can expect complete confidentiality. Reach out today, and let’s find a solution for you.

Our Perspective on Recovery

At All In Solutions, we recognize that recovery is deeply personal, and that individuals come to treatment with different goals, motivations, and definitions of success. We honor those differences and celebrate every meaningful step toward healing, whether it’s improved mental health, better relationships, or reduced substance use.

That said, our program is built around a clear and committed goal: total sobriety. We are not a harm reduction provider. While we respect that approach and understand its role in the broader continuum of care, our clinical philosophy is rooted in helping clients achieve and sustain full abstinence from drugs and alcohol.

We do not teach strategies for “safer” or reduced use. Instead, we equip our clients with the tools, structure, and support they need to build a fulfilling life free from substance use. When clinically appropriate, we support the use of medication-assisted treatment options such as Suboxone or Vivitrol as part of a comprehensive plan focused on long-term recovery.

In short, we believe in going All In—not just on treatment, but on transformation.

Research Methodologies: Strengths and Limitations

Measuring Outcomes Over Time

Studying addiction treatment outcomes presents several challenges. Many early studies focused on short-term endpoints (e.g. whether a patient was abstinent at discharge or at a 90-day follow-up). While useful, these snapshots may not capture the chronic, relapsing nature of substance use disorders. Increasingly, researchers conduct long-term longitudinal studies – following patients for a year, two years, or even longer after treatment – to understand sustained recovery rates. For example, one landmark project (the Prescription Opioid Addiction Treatment Study, POATS) followed patients 42 months (3.5 years) post-treatment, revealing that about half were abstinent at 18 months and even more by 30 months, especially if they engaged in ongoing medication-assisted therapy⁹. Long-term studies like this are crucial to gauge lasting success, but they are also resource-intensive and face high dropout rates.

Follow-Up and Attrition

A major limitation in outcome research is attrition – many participants are difficult to locate or choose not to participate in follow-ups, especially as more time passes. Those lost to follow-up might disproportionately include individuals who relapsed or dropped out, which can bias results. Researchers mitigate this by using larger sample sizes and multiple follow-up attempts, but some bias often remains. It’s noteworthy that even in well-run studies, only a fraction of initial participants may provide data at each follow-up point (for instance, in the study mentioned above, only 57% of the original trial participants enrolled in the long-term follow-up and some of those did not complete every follow-up interview¹⁰). This means outcomes could be somewhat overestimated if those doing well are more likely to respond.

Self-Report vs Objective Measures:

Another methodological issue is how success is measured. Many studies rely on self-reported substance use during follow-up interviews. Self-reports are relatively easy to collect and can cover various substances and behaviors, but they can be prone to under-reporting due to recall issues or social desirability bias. To counter this, some research includes biological measures (like urine drug screens, blood tests for substances, etc.) at follow-ups. These provide objective evidence of use or abstinence, though they typically cover only recent use (e.g. a urine test detects drug use in the past few days or weeks). Combining self-report with periodic drug testing can improve accuracy, but at scale (hundreds or thousands of patients) testing everyone is often not feasible. The Cochrane review of Alcoholics Anonymous (AA) outcomes, for example, noted variability in how outcomes were measured across studies – some looked at continuous abstinence, others at percent days drinking, others at alcohol-related consequences¹¹. Such differences make it challenging to compare results directly across studies.

Defining “Recovery”

As discussed, the very definition of success can vary, which is a limitation when aggregating research. Some studies use a strict outcome (total abstinence for a period); others use composite outcomes (for instance, “no heavy drinking days” as a success measure in alcohol studies, or reduction in drug use frequency by a certain amount). Each definition can yield different “success rates.” For example, one three-year outpatient study of alcohol use disorder found that if success was defined as any improvement in drinking outcomes (not just abstinence), many more patients were counted as successful¹². Researchers must be transparent about their definitions. The strength here is that modern studies increasingly report multiple outcome metrics (abstinence rates, reduction in use, improvements in health indicators, etc.) to give a fuller picture. The limitation is that without a single universal metric, it’s hard for policymakers or the public to answer “what is the success rate of rehab?” in a simple way – it truly depends on how success is defined and measured.

Randomized Trials vs Real-World Data

When evaluating specific treatment modalities, randomized controlled trials (RCTs) are the gold standard to test efficacy (e.g. comparing a new therapy to standard counseling). RCTs minimize biases by randomly assigning participants, but they often have strict inclusion criteria and controlled conditions that may not reflect real-world diversity. On the other hand, observational studies (like SAMHSA’s Treatment Episode Data Set or follow-ups by treatment centers) include “real-world” patients in large numbers, but without control groups it’s harder to attribute outcomes to the treatment itself versus patient characteristics. Each approach has strengths: RCTs can demonstrate that a modality can produce better outcomes than a comparison treatment (e.g. studies showing 12-step facilitation can yield higher abstinence rates than cognitive-behavioral therapy in some cases¹³), while large-scale databases like TEDS show average outcomes across the nation (e.g. what proportion of all treatment episodes end in completion or dropout¹⁴). Long-term cohort studies blend these approaches but are hard to execute, and self-selection bias is a concern (patients who stay in treatment or studies may be inherently more motivated). In sum, outcome research in addiction is complex – each methodology has limitations – so the strongest conclusions come from converging evidence across multiple study designs.

Success Rates by Level of Care

Inpatient vs Outpatient

The level of care – meaning the intensity and setting of treatment – is a key factor in completion and success rates. Broadly, more intensive levels (like inpatient/residential treatment) tend to have higher completion rates than less intensive outpatient programs. National data from SAMHSA’s Treatment Episode Data Set (TEDS) illustrate this clearly. For example, in 2018, about 76% of discharges from hospital inpatient rehabilitation were classified as completed, whereas only around 42% of discharges from standard outpatient programs were completed¹⁵ ¹⁶. Intensive Outpatient Programs (IOPs), which are an enhanced form of outpatient treatment with multiple sessions per week, showed intermediate success – roughly half of IOP patients completed treatment in national statistics¹⁷. These numbers indicate that retention is more challenging in outpatient settings, likely because patients remain in their home environment with easier access to substances and more competing demands on their time (work, family) that can interfere with treatment attendance. In an inpatient setting, by contrast, patients are in a controlled, substance-free environment with 24/7 support, making it easier to stay until the planned discharge.

It’s important to note that these are completion rates, not long-term sobriety rates. Yet, completion matters: patients who finish the full course of treatment have better odds of favorable long-term outcomes than those who leave early. Research confirms a strong correlation between completing treatment and subsequent abstinence. One analysis found that about 60% of patients who completed treatment were abstinent 12 months later, versus only ~42% of those who left against staff advice. In other words, dropping out early significantly lowered the chances of staying sober at one year. This holds true across levels of care. Hazelden Betty Ford Foundation’s 2023 outcomes report similarly noted that being discharged with staff approval (i.e. having stayed for the recommended duration) cut the odds of relapse in half at 12 months post-treatment¹⁸. Thus, the higher completion rates in residential care likely translate into better long-term success for those patients, whereas outpatient programs must grapple with keeping clients engaged.

Partial Hospitalization (PHP) and IOP

Partial Hospitalization is a step-down from inpatient – patients attend day-long treatment but go home at night. It’s often grouped with Intensive Outpatient Programs in the “outpatient” category. National studies don’t always separate PHP, but data suggest PHP/IOP completion rates are higher than standard outpatient yet still lower than residential. All In Solutions (a treatment organization discussed later) noted that national studies lack PHP-specific benchmarks, so IOP averages are often used as a proxy. They cited ~26% completion as a national figure for outpatient programs comparable to PHP/IOP (this 26% likely refers to non-intensive outpatient in the 2018 data, underscoring how definitions can vary – other analyses indicate IOP completion closer to ~50%, while less intensive “outpatient therapy” can have completion rates in the 20–30% range¹⁶). The takeaway is that as structure and intensity drop, so do completion/success rates on average. Patients in less-structured care may find it easier to relapse or disengage. This is why clinicians stress proper placement: someone with a severe SUD or unstable home may do far better in residential care initially than in basic weekly outpatient counseling.

After Inpatient – the Continuum of Care

It’s not that inpatient is “better” in an absolute sense – rather, different levels serve different needs. Many effective treatment plans are stepwise: e.g. 4 weeks inpatient, then transition to IOP or outpatient, then continuing care. Notably, some studies find that long-term outcomes can equalize if patients receive ongoing support after inpatient. For instance, a person who completes 28 days inpatient and then engages in weekly therapy and AA may have similar one-year sobriety rates to someone who did a longer IOP and sober living arrangement – if both remained in some form of care for an adequate time. However, if outpatient clients drop out early (a common issue), their outcomes suffer. Residential treatment can essentially “buy time” for an individual to stabilize and build motivation in a protected setting. Indeed, outcome statistics often show initial post-treatment abstinence rates are higher for inpatient completers. One summary statistic reported that among those who complete inpatient programs, roughly 60–70% report abstinence up to 9–12 months post-discharge, whereas those who only did outpatient had lower abstinence rates unless they also engaged in substantial continuing care¹⁸. In summary, inpatient and residential programs have higher short-term success rates (in terms of completion and early abstinence), while outpatient programs have the advantage of lower cost and flexibility but struggle with retention. Matching patients to the appropriate level (using criteria like ASAM Patient Placement Criteria) is crucial: a well-matched outpatient client who is stable and highly motivated might do very well, but someone with repeated relapses may need the jump-start of inpatient care to achieve initial sobriety.

Impact of Length of Stay in Treatment

Research consistently finds that longer treatment duration correlates with better outcomes. Addiction is not resolved overnight, and sufficient time in therapy is needed to effect lasting behavior change. A widely cited guideline from NIDA states that “most addicted individuals need at least 3 months in treatment to significantly reduce or stop drug use… the best outcomes occur with longer durations”¹⁹. This does not necessarily mean 3 months all in one setting, but rather a combination of levels of care totaling 90+ days (for example, a 30-day residential stay followed by 60 days of intensive outpatient).

Programs lasting shorter than this may still help, but success rates tend to be lower.

Data back this up: One analysis noted that programs lasting 90 days or more show a marked increase in success rates, with outcomes improving the longer someone remains engaged in treatment. In practical terms, patients who stay in any form of treatment for three months or more are more likely to be abstinent and functioning well at follow-up than those with, say, only a 2-week detox or a month of counseling. There appears to be a threshold effect around that 3-month mark, after which additional gains may continue more gradually²⁰. For example, methadone maintenance treatment for opioid use disorder often needs to be sustained for years, not weeks, to maintain recovery – many patients experience relapse if medication is tapered too quickly (which is essentially shortening the “length of stay” on MAT).

Early Drop-Out = Poor Outcomes

Conversely, leaving treatment early is a strong predictor of relapse. As mentioned, those who leave against medical advice have significantly lower abstinence rates at 6- and 12-month follow-ups¹⁸. Many programs therefore focus on improving retention – through motivational techniques, engagement strategies, or even logistical help (transportation, childcare) to keep patients coming. Some innovations like contingency management (providing small rewards for each negative drug test or session attended) have been shown to extend length of stay in outpatient programs, which in turn improves outcomes. The logic is simple: the more time someone spends actively working on recovery skills and not using substances, the better their chances of internalizing those changes.

Continuing Care Matters

Length of stay can also be viewed in the context of continuing care/aftercare. Many patients have multiple episodes of treatment over the years. Someone might have 30 days residential, relapse after 2 months, then go to an outpatient relapse prevention group for 6 months, etc. Each episode adds to the total “dose” of treatment. Studies of continuing care show that patients who engage in some form of ongoing care after initial treatment – be it 12-step groups, alumni programs, or periodic counseling – have higher rates of long-term sobriety. Essentially, successful recovery often requires a long-term management approach. In chronic disease terms, just as a few weeks of medication may not cure hypertension, a few weeks of rehab may not “cure” addiction – continuous or repeated treatment might be needed to manage the condition. One systematic review found that patients who received at least a year of follow-up support (vs. those who did not) had significantly higher odds of abstinence at 18+ months, underscoring the value of extending care duration²¹.

In summary, staying in treatment longer is strongly associated with higher success rates. Short interventions can help kick-start recovery, but adequate treatment “dosage” (often cited as ≥90 days) is linked to better outcomes on measures of abstinence, relapse prevention, and psychosocial functioning¹⁹. Programs therefore aim to engage patients for as long as needed – using phase-down approaches (inpatient → outpatient → aftercare) rather than an abrupt stop. This sustained engagement is one reason why, for example, drug court programs mandate long-term treatment and monitoring (often a year or more) for participants, leading to lower re-arrest rates and substance use compared to short jail stays without treatment²². Consistent care over time helps “rewire” habits and support lasting change.

Variation by Primary Substance Used

Outcomes can vary significantly depending on the primary substance of abuse, due to differences in addiction severity, available treatments, and relapse patterns for different drugs. Here are some key patterns observed by substance type:

Alcohol

While alcohol is one of the most commonly treated substances, recovery outcomes can vary widely based on factors like treatment length and co-occurring conditions. Explore what the research says about success rates and long-term sobriety for alcohol use disorder.

Opioids

Treating opioid addiction often involves a combination of behavioral therapy and medication-assisted treatment. Learn how these approaches impact recovery outcomes and what success looks like for individuals with opioid use disorder.

Stimulants

Recovery from stimulant addiction presents unique challenges, especially due to the lack of FDA-approved medications. Discover what current studies reveal about treatment success for cocaine and methamphetamine use.

Poly-Substance Abuse

When individuals struggle with more than one substance, recovery becomes more complex—but not impossible. Learn how integrated treatment approaches support those facing polysubstance use disorders.

Individual Factors Affecting Success Rates

Social Support

Most critical factor: Strong social networks (family, friends, recovery groups) are consistently linked to better outcomes³⁹
Family involvement in treatment and supportive spouses reduce relapse rates
Involvement in sober peer networks (12-step groups, sober living homes) significantly improves long-term abstinence
Returning to environments where others use substances increases relapse risk
Social isolation and stigma impede success, while community acceptance enhances it

Criminal Justice Involvement

Mandated vs. voluntary treatment: Contrary to expectations, patients who enter treatment under legal pressure (court-mandated, drug court programs, probation) often perform as well as or better than voluntary patients³⁶
External pressure principle: Family ultimatums, employer threats, or other forms of external pressure can be equally effective catalysts for treatment entry – once engaged, treatment outcomes depend more on active participation than on the initial motivation for entering³⁷ ³⁸
External incentives and accountability can improve treatment retention and outcomes
Success rates for court-referred clients are comparable to self-referred clients when they complete programs

Education and Socioeconomic Status

Higher education/employment correlates with better outcomes, likely due to greater social stability, resources, and problem-solving skills
Lower socioeconomic status can create barriers through increased stress and fewer resources
However, once in treatment, people from all backgrounds can benefit significantly
Employment after treatment is strongly associated with reduced relapse rates.

Co-occurring Mental Health and Trauma

Untreated psychiatric disorders (depression, anxiety, PTSD) negatively affect success rates⁴¹
Integrated treatment addressing both substance use and mental health improves outcomes
Trauma history complicates recovery unless trauma-informed care is provided
Dual-diagnosis capable programs show higher success rates⁴²

Personal Motivation and Recovery Capital

“Recovery capital” refers to personal resources supporting recovery (coping skills, health, spirituality, sense of purpose)
High recovery capital correlates with better long-term recovery odds⁴⁴
Treatment can help build recovery capital through skill development and improved self-efficacy

Outcomes by Treatment Modality (12-Step, CBT, MAT, Etc.)

Treatment for substance use disorders can follow various modalities or approaches, and their success rates and outcome profiles can differ. It’s important to interpret outcome data in context – some modalities are better at achieving complete abstinence, others excel at reducing harm or improving engagement. Below we compare major modalities:

12-Step Facilitation and Mutual Support Programs:

The 12-step model (embodied by peer fellowships like Alcoholics Anonymous and Narcotics Anonymous, as well as the professional 12-step facilitation therapy used in many programs) is one of the most ubiquitous approaches. Its effectiveness was debated for years, but recent high-quality studies and a comprehensive Cochrane meta-analysis in 2020 confirmed strong outcomes. Manualized 12-step facilitation programs produced higher rates of continuous abstinence than other psychosocial treatments (like CBT or motivational enhancement therapy) in the long term¹³. Specifically, AA/TSF showed an advantage in achieving total abstinence and in increasing the percentage of days abstinent, especially evident at 12+ months follow-up¹⁴.

For example, one large trial found that patients in a 12-step facilitation therapy had about 36% continuous abstinence at one year, versus 24% for those in cognitive-behavioral therapy – a statistically significant difference⁴⁶. Moreover, 12-step involvement is linked to sustained recovery: those who actively participate in AA/NA meetings have much lower relapse rates. Many achieve multi-year sobriety with ongoing fellowship support – one reason professional treatment often encourages meeting attendance.

Another outcome to note is cost-effectiveness: the Cochrane review found 12-step approaches can reduce healthcare costs (due to potentially fewer relapse-related hospital visits) while yielding equal or better outcomes. It’s not that 12-step works for everyone – some individuals prefer alternative support groups – but when engagement is strong, success is notable. In summary, outcome data for the 12-step modality (including TSF therapy and community AA/NA participation) show high abstinence rates in those who stick with it; a substantial portion of participants achieve long-term sobriety, and even those who do not achieve total abstinence often reduce their drinking/drug use and related consequences⁴⁷.

Cognitive Behavioral Therapy (CBT):

CBT is a short-to-medium term psychotherapy approach that teaches skills to manage cravings, avoid triggers, and cope with thoughts and behaviors that lead to substance use. It is a well-established, empirically supported treatment across many addictions⁴⁸. Meta-analyses indicate that CBT for SUD produces significant improvements compared to no treatment – one review found CBT outcomes were roughly 15–25% better than control conditions in terms of reduced substance use⁴⁹. However, when CBT is compared to other active treatments (like motivational interviewing or 12-step facilitation), the differences are often small.

Notably, CBT’s effects are strongest in the early months after treatment and may diminish over time if not reinforced⁵⁰. In one analysis, CBT showed the greatest efficacy at 1–6 months post-treatment, but by 12 months the advantage had lessened as many patients in all groups had either relapsed or improved, narrowing the gap⁵¹. This suggests that while CBT teaches useful coping strategies that can immediately reduce use (small-to-moderate effect sizes short-term), ongoing practice and booster sessions might be needed to maintain long-term gains.

Indeed, follow-up studies of CBT-treated patients often find that many relapse at some point (similar to other therapies), but those who consistently applied CBT skills had better long-term outcomes than those who did not. Overall, CBT is a critical component in many treatment programs and is effective at engaging patients in the process of change. Its strength lies in flexibility and skill-building, which can address a range of issues from drug refusal techniques to managing negative moods. Many rehab centers report good internal success rates with CBT-oriented curricula, especially for stimulant or cannabis use disorders where no medications are available.

The key takeaway: CBT helps most patients reduce substance use and improve psychosocial functioning; it’s roughly on par with other structured therapies in achieving long-term abstinence, but it remains a cornerstone due to its robust evidence base and adaptability⁵² ⁵³. Combining CBT with other modalities (e.g. CBT plus 12-step, or CBT plus medication) often yields the best results.

Medication-Assisted Treatment

MAT refers to the use of FDA-approved medications in combination with counseling, particularly for opioid and alcohol use disorders. The outcomes with MAT are among the most positive in addiction treatment, especially for opioid addiction.

For Opioid Use Disorder, as noted earlier, medications like methadone and buprenorphine lead to dramatically higher treatment retention and success in suppressing illicit opioid use. Success for MAT is often measured in terms of treatment retention and reduction in illicit use rather than immediate abstinence from all opioids (since patients may be maintained on an opioid medication). By those measures, MAT yields success rates in the range of 50–60% at 12 months – meaning a majority of patients on MAT either remain in treatment with no illicit opioid use or have prolonged periods of abstinence punctuated by only occasional lapses⁵⁴ ⁵⁵. In contrast, opioid patients not on MAT have one-year abstinence rates typically under 20% in many studies. Furthermore, long-term cohorts show that continued MAT can sustain recovery for many years. Methadone maintenance programs often report that well over half their patients provide opioid-negative drug tests at any given time and achieve improvements in employment and criminal behavior.

For Alcohol Use Disorder, MAT includes naltrexone, acamprosate, and disulfiram. These medications have more modest effects than opioid MAT, but can still improve outcomes: for example, oral naltrexone has been shown to increase the rate of abstinence or non-heavy-drinking by about 10% over placebo, and extended-release injectable naltrexone likewise helps reduce relapse risk. Acamprosate helps increase continuous abstinence duration, according to meta-analyses. While these effect sizes are moderate, when combined with therapy, they raise overall success probabilities. In practice, many alcohol treatment programs that utilize medications report higher 6–12 month sobriety rates than programs that do not.

MAT for tobacco (nicotine replacement therapy, bupropion, varenicline) also greatly improves quit rates and is considered standard of care.

To sum up, MAT is one of the most evidence-backed modalities, particularly shining in opioid addiction: it not only improves success rates in terms of reduced use and increased abstinence, but also reduces overdose deaths and other medical complications (an undeniable measure of success in itself)⁵⁶. Outcomes data clearly favor MAT for opioids – one might say the “success rate” for opioid addiction roughly doubles with MAT compared to without. For alcohol and nicotine, medications can similarly tilt the odds in the patient’s favor, though they are typically used alongside behavioral treatments.

Residential Therapeutic Communities (TCs):

Long-term residential programs (often 6–12 months) following the “therapeutic community” model were historically used for severe addictions, including those with criminal justice involvement. These programs emphasize behavioral change within a highly structured community setting. Outcomes from classic TCs like Synanon, Daytop, or Phoenix House have shown that longer stays (12+ months) result in lower drug use and criminality post-treatment.

For instance, one review of therapeutic communities found that participants who completed a full year had significantly lower rates of drug use and incarceration 5 years later compared to those who left earlier⁵⁷.

However, TCs also have high dropout rates, with many clients leaving in the early months. Those who do complete often represent a self-selected, highly motivated group – and their success rates can be quite high (some studies showing 70–80% abstinence at 1–2 years among completers).

Modern residential rehab programs (shorter 30–90 day stays) are shorter than traditional year-long TCs, but still show benefits of a drug-free environment with intensive therapy. As noted earlier, completion rates in short-term residential rehab average about 50% nationally⁵⁸, but among those who complete, outcomes are strong. Hazelden Betty Ford’s data indicate around 60% of residential patients who complete treatment are sober at 12-month follow-up¹⁸. Likewise, government research (e.g. the DATOS studies) found significant reductions in drug use and arrests in the year after residential treatment, especially for those who engaged in aftercare.

In summary, residential modalities (whether long therapeutic communities or shorter rehab stays) tend to produce substantial short-term improvements; their longer-term success is highest when followed by continuing care. They are particularly useful for patients with unstable home environments or multiple failed attempts at outpatient treatment. The immersive nature jump-starts recovery, and many patients report improvements in mental health and social functioning as well. For example, one study reported improved depression symptoms and employment status after a residential program, correlating with longer stay durations⁵⁹.

Thus, residential treatment can claim some of the highest success rates at program completion (often 60–80% of clients leave abstinent), but maintaining those gains requires transition to lower levels of care rather than abrupt discharge.

Outpatient Counseling:

Standard outpatient treatment (e.g. weekly individual or group counseling sessions) has the lowest completion rates and often lower abstinence rates during treatment, as discussed. However, “outpatient” is a broad category – outcomes vary widely depending on the intensity and patient engagement. Some data suggest that only ~43% of clients complete outpatient episodes successfully⁶⁰ ¹⁶. That said, outpatient is often used for mild SUD or as a step-down level of care, so expectations differ.

For a motivated individual with a mild substance problem, weekly counseling might be sufficient and yield a great outcome (full remission). On the other hand, someone with severe dependence might continue using while in standard outpatient, leading to a “treatment failure.”

Success in outpatient often relies on external structure: individuals who have stable routines, supportive family, and perhaps concurrent involvement in support groups do much better. A notable portion of outpatient treatment clients do achieve sobriety – for instance, a study of an outpatient program for alcohol found that about 30% were continuously abstinent at 6 months and another 20–30% significantly reduced drinking⁶¹. With ongoing care beyond the formal outpatient sessions, these numbers can climb.

Outpatient is also the most accessible modality, so it catches people who might not attend more intensive programs. Success in a public health sense includes those who reduce harm (even if they continue to use occasionally – for example, fewer binge episodes or fewer injection drug use events can be considered a success). In sum, outpatient modalities have high variability in outcomes. Their success rates (in terms of abstinence or completion) are generally lower than more intensive modalities, but they are an indispensable part of the continuum, especially for those stepping down from higher care or those with milder SUD. When combined with medications or recovery coaching, standard outpatient can approximate the success of intensive outpatient in some cases.

Other Modalities:

There are other approaches like Motivational Enhancement Therapy (MET), which is often a brief intervention used to increase readiness to change – it has proven effective in engaging patients and can increase the probability of entering further treatment (success in that context is movement along the stages of change).

Contingency Management (CM), as mentioned earlier, has some of the highest short-term abstinence rates for stimulants – studies have shown CM can produce 8–12 weeks of continuous cocaine abstinence in around 40–50% of participants, far outperforming the typical ~5–10% in therapy-alone conditions⁶². The challenge is sustaining it once the incentives stop, but its success in initiating abstinence is notable and it’s being expanded for opioids (in methadone clinics) and other drugs.

Family therapies (like MDFT for adolescents or CRAFT for loved ones) have high success in engaging resistant individuals and improving outcomes in certain groups (especially adolescents), though for adults these are often used as adjuncts to other treatments.

Finally, newer modalities like meditation/mindfulness-based relapse prevention and Acceptance and Commitment Therapy (ACT) show promise – one study found ACT slightly outperformed CBT in maintaining abstinence at end of treatment (27% vs 16% in one trial)⁶³, though research is ongoing.

Summary of Therapies

In summary, each modality has its strengths: 12-step approaches excel in long-term abstinence and community-building, CBT provides solid coping skills and short-term benefit, MAT dramatically improves outcomes for opioid disorders (and helps for alcohol/nicotine), residential programs achieve high initial sobriety and life stabilization, and outpatient offers accessible ongoing support (with success boosted by combining it with some of the above).

The best outcomes often result from combining modalities – for instance, an opioid user on buprenorphine (MAT) who also receives CBT and attends NA meetings is addressing the biological, psychological, and social facets of the disorder. Such comprehensive approaches yield the highest success rates, as each modality addresses different aspects of addiction. Notably, many programs are integrated, so a single rehab may employ CBT + 12-step + MAT + family therapy, etc., making it hard to attribute success to one modality alone. Nonetheless, understanding each component’s impact helps optimize treatment planning for different individuals.

Rehabs with the Highest Success Rates in U.S.

All In Solutions Success Rates (Comparison to National Benchmarks)

In this section, we examine outcome data from All In Solutions, a treatment provider that compiled its performance indicators for 2024, and compare these to national benchmarks. The focus is on program completion rates, client satisfaction, and clinical outcome measures, benchmarking All In Solutions (AIS) against U.S. averages.

Program Completion Rates:

All In Solutions reported notably high completion rates in 2024 across its programs. In their inpatient services (which include detox and residential rehab), 82% of clients successfully completed the program (i.e. remained in treatment until clinically discharged). This is well above the national average completion rate for similar inpatient treatment. The latest U.S. data (Treatment Episode Data Set, 2018) shows about 52% completion for inpatient/residential treatment nationally. All In Solutions’ inpatient completion is approximately 30 percentage points higher than the national average, a substantial difference.

For outpatient services, All In Solutions offers PHP/IOP level care. In 2024 they had a 76% successful completion rate in PHP/IOP programs. National benchmarks for intensive outpatient treatment indicate much lower completion – All In cites the national average IOP completion around 26%. Even if one uses other sources that put IOP completion closer to ~50%, the AIS rate is still significantly higher. Using the figure given in the AIS report (26%), All In Solutions’ 76% represents roughly 50 percentage points above the average outpatient completion rate. This suggests that All In Solutions is managing to engage and retain a far greater proportion of its outpatient clients through to completion than typical programs do. Such differences could be due to various factors: AIS may have smaller case loads, more individualized attention, strong engagement practices, or ancillary supports that improve retention (their report doesn’t specify causes, but the data speak to exceptional retention).

These comparisons illustrate that All In Solutions substantially outperforms national norms in terms of retaining clients to completion. For context, as discussed earlier, completion is a critical metric since it correlates with better post-treatment outcomes. The AIS report even references that the national data is from 2018 – highlighting that their 82%/76% completion rates in 2024 are current outcomes beating those benchmarks. Even if overall national rates have inched up since 2018 (for example, due to system improvements by 2024), it’s unlikely they would reach the levels AIS is reporting. So, AIS appears to be an outlier on the positive side. We should caution that AIS’s clientele or program structure could differ from average (e.g., they might have smaller facilities or different admission criteria), but absent that detail, the numbers speak to effective retention strategies.

Program Completion Across AIS Locations

Percent of Clients Who Successfully Completed Our Programs 2024 vs National Average.

As part of our commitment to meeting each client’s individual needs, comprehensive client satisfaction surveys are administered at discharge after successful program completion.

Client Satisfaction:

All In Solutions also tracks client satisfaction via surveys at discharge. According to their 2024 report, 93% of clients were satisfied with their overall experience at All In Solutions facilities. This indicates an overwhelmingly positive appraisal by patients. The report breaks down satisfaction into specific aspects: for instance, 95% of clients were satisfied with the accommodations and safety of the facilities, and similarly high ratings were given to clinical domains – 97% felt satisfied with their treatment planning process, 96% were satisfied with the therapists/counselors, 94% were satisfied with the educational components, and 92% felt their medical/psychiatric needs were handled appropriately. These figures (mostly in the 90s) reflect an excellent level of satisfaction across both environment and clinical care dimensions.

Comparing this to national benchmarks is a bit tricky, as there isn’t a single standardized national patient satisfaction score for addiction treatment. However, we can say that 93% overall satisfaction is very high by any healthcare standard. Many treatment programs do collect satisfaction data, often reporting high marks (since those who complete treatment are generally appreciative). For instance, Hazelden Betty Ford surveys its alumni on quality of life and indirectly satisfaction – they found 88% of patients rated their quality of life good or better a year after treatment, which suggests sustained satisfaction with the outcomes of treatment. While not directly comparable (quality of life vs. program satisfaction at discharge), both indicate positive experiences. Another data point: a 2019 survey of state-funded treatment programs found average satisfaction ratings around 85–90% “satisfied” when combining “very satisfied” and “satisfied” responses – again, quite high, but All In Solutions’ 93% is at the upper end of the range. It’s worth noting that those who drop out of treatment are often not included in such surveys (AIS’s survey count was 1,329 in 2024, likely only those who participated at discharge). So, satisfaction results naturally skew toward completers. Nevertheless, All In Solutions’ satisfaction scores indicate that the vast majority of their clients felt the treatment met or exceeded their expectations.

Symptom Improvement (PHQ-9 & GAD-7):

In addition to retention and satisfaction, AIS’s 2024 outcomes report tracked changes in clients’ depression and anxiety levels using validated scales (the Patient Health Questionnaire-9 for depression and the Generalized Anxiety Disorder-7 for anxiety). The data show significant improvements in these mental health measures from intake to discharge, reflecting the effectiveness of AIS’s clinical care for co-occurring issues. In the inpatient-only cohort (clients who received detox/residential treatment at AIS Wellness Center FL or AIS Detox CA and then discharged without stepping down to AIS outpatient), average PHQ-9 scores dropped by ~3 points from admission to discharge – roughly a 45% reduction in depression severity. Their GAD-7 anxiety scores likewise fell by nearly 48% on average during the inpatient stay. Clients who attended outpatient programs only (PHP/IOP at AIS Counseling Centers in FL, NJ, or CA without prior AIS inpatient) started with lower baseline scores (~6–8 out of 21 on the scales), but still saw those scores roughly halved by the end of treatment. For example, at the New Jersey outpatient center, the average PHQ-9 fell from 8.0 upon intake to 2.9 at discharge, and GAD-7 from 8.2 to 3.0. Across AIS’s three outpatient facilities, discharge PHQ-9 averages in 2024 were around 3–4 (down from ~6–8 at intake) and GAD-7 averages around 3–4 as well, indicating marked relief of symptoms.

Notably, the full continuum of care group – patients who completed a detox/residential phase and then stepped down into PHP/IOP (for instance, transitioning from AIS West Palm Beach detox to the Florida outpatient program) – experienced the greatest gains. In Florida, these clients’ PHQ-9 scores plummeted from an average of 14.3 at intake to just 3.9 at final discharge, and in California from 16.4 to 4.3. This represents roughly a 72–73% reduction in depression severity for full-continuum clients. Their anxiety levels showed a similarly dramatic drop: GAD-7 scores fell about 70% (from around 14–15 at admission to about 4 at discharge) for full-continuum graduates in both Florida and California. In practical terms, these patients entered treatment with moderate-to-severe anxiety and depressed mood, and by the time they completed the entire continuum of care, their average scores were in the low single digits.

These improvements are clinically meaningful. By discharge, average PHQ-9 and GAD-7 scores across all groups had fallen into the “minimal” symptom range (scores below 5)⁶⁴ ⁶⁵, indicating that many AIS clients left treatment with little to no clinically significant depression or anxiety remaining. Essentially, on average, patients went from moderate levels of depression/anxiety at intake to minimal levels at completion of the program – an outcome suggesting a full remission of these symptoms for a large portion of clients. Achieving such drastic symptom relief is notable. In general mental health treatment, a 50% reduction in PHQ-9 or GAD-7 scores is often considered a strong positive response to therapy⁶⁶. AIS’s full-continuum patients far exceeded that benchmark, averaging around a 70% improvement on both scales.

For instance, a recent outcome study of an enhanced recovery intervention reported a 71.5% drop in depression and a 58.5% drop in anxiety among adults in addiction treatment⁶⁷ – figures in the same ballpark as AIS’s results, which in the case of anxiety are even higher. This comparison suggests that All In Solutions’ integrated approach to treating substance use and co-occurring mental health conditions is yielding symptom improvements that align with or surpass expectations based on existing outcome research. It’s also important to note that co-occurring depression and anxiety are common in substance use disorder populations and can be risk factors for relapse. The substantial reduction of these symptoms at AIS likely enhances their clients’ overall prognosis, as improved mental health can reinforce sustained recovery.

In conclusion, All In Solutions stands well above national benchmarks in treatment completion rates and clinical outcomes, and it matches or exceeds typical satisfaction levels. This bodes well for their clients’ long-term success, since, as discussed, completing treatment, experiencing relief from co-occurring mental health symptoms, and being satisfied with care (which often correlates with having one’s needs met) are positive predictors for sustained recovery. The data from AIS’s 2024 “By the Numbers” report, when viewed alongside national statistics, highlight what is possible in addiction treatment outcomes and set a high bar that other providers may look to for quality improvement.

Take the First Step

If you or a loved one is ready to seek treatment, our admissions team is available 24/7 to assist you through the process. Our admissions specialists will answer your questions about insurance and help you find the level of care that works best for you.

Sources

National data and research reports were used for benchmarks and context[15][34][43]. All In Solutions’ 2024 outcomes were drawn from their published report. These comparisons are intended to be objective, recognizing that patient populations and methodologies differ, but they provide a general yardstick of success rates in addiction treatment today.

[1] [2] [3] [7] [8] [35] [41] Reduced drug use is a meaningful treatment outcome for people with stimulant use disorders | National Institute on Drug Abuse (NIDA)

https://nida.nih.gov/news-events/news-releases/2024/01/reduced-drug-use-is-a-meaningful-treatment-outcome-for-people-with-stimulant-use-disorders

[4] [5] [36] [73] Hazelden Betty Ford: Treatment Results and Patient Outcomes

https://www.hazeldenbettyford.org/about/treatment-success-rates

[6] How Do Your Treatment Completion Rates Compare? | Vista Research Group

https://vista-research-group.com/treatment-completion-rates

[9] [10] [11] [39] [40] Long-Term Treatment Outcomes for Individuals with Opioid Use Disorders – Recovery Research Institute

https://www.recoveryanswers.org/research-post/long-term-treatment-outcomes-for-individuals-with-opioid-use-disorders/

[12] [13] [14] [33] [34] [53] Alcoholics Anonymous (AA) and other 12-step programs for alcohol use disorder | Cochrane

https://www.cochrane.org/evidence/CD012880_alcoholics-anonymous-aa-and-other-12-step-programs-alcohol-use-disorder

[15] [16] [17] [20] [23] [24] [37] [38] [75] Addiction Treatment: Statistics on Efficacy – Addiction Group

https://www.addictiongroup.org/resources/treatment-statistics/

[18] [27] [28] [29] [50] Patient Outcomes Study Results | Rehab Success Rates

https://www.hazeldenbettyford.org/research-studies/addiction-research/patient-outcomes-study

[21] [22] 2018 TEDS Annual Report

https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html

[25] [32] [48] [49] Principles of Drug Addiction: A Research-Based Guide (Third Edition)

https://nida.nih.gov/sites/default/files/podat-3rdEd-508.pdf

[26] [43] [51] Welcome

https://webcampus.med.drexel.edu/nida/module_1/content/5_0_Treatment.htm

[30] [31] A systematic review and meta-analysis of the efficacy of the long …

https://www.sciencedirect.com/science/article/abs/pii/S0277953621006213

[42] Impact of recent stimulant use on treatment outcomes amongst …

https://www.sciencedirect.com/science/article/pii/S2772724625000137

[44] [45] [46] [47] Social Support Influences on Substance Abuse Outcomes Among Sober Living House Residents with Low and Moderate Psychiatric Severity – PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC5529042/

[52] Let’s not turn back the clock: Comments on Kelly et al., “Alcoholics …

https://academic.oup.com/alcalc/article-abstract/56/4/377/6034029

[54] [56] [61] An Evaluation of Cognitive Behavioral Therapy for Substance Use Disorder: A Systematic Review and Application of the Society of Clinical Psychology Criteria for Empirically Supported Treatments – PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC10572095/

[55] [PDF] Journal of Consulting and Clinical Psychology – UCLA Addictions Lab

https://addictions.psych.ucla.edu/wp-content/uploads/sites/160/2020/01/JCCP-A-meta-analysis-of-cognitive-behavioral-therapy-for-alcohol-or-other-drug-use-disorders-Treatment-efficacy-by-contrast-condition.pdf

[57] Factors associated with abstinence in addiction inpatient treatment …

https://www.tandfonline.com/doi/full/10.1080/14659891.2023.2226204

[58] An Evaluation of Drug Treatments for Adolescents in 4 US Cities

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/481800

[59] Does Length of Stay Make a Difference in Drug and Alcohol …

https://www.aristarecovery.com/blog/does-length-of-stay-matter-in-addiction-treatment

[60] How useful is abstinence alone in understanding the effectiveness …

https://www.recoveryanswers.org/research-post/abstinence-treatment-outcomes/

[62] Effects of cognitive behavioral therapy (CBT) on addictive symptoms …

https://www.sciencedirect.com/science/article/abs/pii/S0165178125000745

[63] Effectiveness of acceptance and commitment therapy for addictive …

https://www.sciencedirect.com/science/article/pii/S221214472400053X

[64] [66] PHQ-9: Validity of a Brief Depression Severity Measure

https://pmc.ncbi.nlm.nih.gov/articles/PMC1495268/

[65] ADAA GAD-7

https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf

[67] Trait-based recovery enhances engagement and reduces anxiety and depression symptoms

https://www.nature.com/articles/s41598-025-06384-0